A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease

NCT02214121 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease

Interventions

DRUG: Ticagrelor Dose 1a + Dose 2a
DRUG: Ticagrelor Dose 1b + Dose 2b

Sponsor

AstraZeneca